ZYBERNO
Stock Report
Updated Aug 23, 2026

KONINKLIJKE PHILIPS NV (RYLPF)

Healthcare • OTC

$27.58

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
9.0/100
POOR BUSINESS
KONINKLIJKE PHILIPS NV (RYLPF) scores 9/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
MARGIN OF SAFETY
Is this stock cheap or expensive relative to what the business has historically generated for owners?
Margin of Safety unavailable — insufficient data for the owner-earnings DCF.
Is the market underestimating or overestimating what this business is capable of going forward?
-17.6%
Market Overestimates
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):AVERAGE (0.64x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):POOR (7.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

KONINKLIJKE PHILIPS NV (RYLPF) stock report — Zyberno Score 9/100 (POOR BUSINESS). Full financial analysis on Zyberno.

According to Zyberno's DCF model, KONINKLIJKE PHILIPS NV (RYLPF) shows a Brina Gap of -17.6%, which weakens the case: based on the company's ROIC (7.0%) and reinvestment rate (-98.7%), the business can fundamentally grow at -6.9% — but the current enterprise value implies the market expects 10.6%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:27.58
Market Cap:$26.56B

Valuation Multiples (2)

P/B Ratio:2.09x
Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$31.40B
Ev Ebitda Ratio:9.89x

Price Action & Momentum (3)

Momentum Percentile:49 / 100
% of 52-Week High:99.6%
B. Profitability Assessment

Return Metrics (5)

Reinvestment Rate:-98.7%
Fundamental Growth Rate (g):-6.9%
Market-Implied Growth Rate:10.6%

Margin Analysis (1)

Ebitda Margin:15.4%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:1.4%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.32x
Quick Ratio:0.94x
Cash Ratio:0.37x

Leverage Analysis (3)

Debt To Equity Ttm:0.64x
Debt-to-Equity Ratio:0.64x
Debt To Ebitda:2.54x

Coverage Ratios (2)

Interest Coverage Ratio:4.12x
Times Interest Earned:4.12

Capital Structure (4)

Working Capital:2,799,534,200.00
Cash And Cash Equivalents:3,228,187,600.00
Long Term Debt:$8.01B
Net Debt:$4.84B
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$20.61B
Cost Of Revenue Ttm:$11.30B

Profitability Breakdown (2)

$9.31B$1.65B

Bottom Line Performance (3)

$1.04B
Income Before Tax:$0.00
Ebitda Ttm:3,173,883,800.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:$325.82M
Interest Expense:399,768,400.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:15.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$31.13B
Current Assets:$11.48B
Ppe Net:2,868,858,200.00
Goodwill:10,711,713,400.00
Intangible Assets:$2.97B

Liability Structure (4)

Total Liabilities:18,433,251,600.00
Current Liabilities:8,675,898,600.00
Long Term Debt:$8.01B
Short Term Debt:$60.08M

Equity & Capital (3)

Equity:$12.70B
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:4,078,562,000.00
Inventory:3,315,998,000.00
Accounts Payable:2,226,455,800.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

$0.00$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$0.00
Dividends Paid Ttm:378,971,200.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:$1.08

Revenue & Cash Per Share (2)

Sales Per Share Ttm:21.40
Operating Cash Flow Per Share:-$999.00

Book Value & Capital (2)

Book Value Per Share:$13.19
Cash Per Share:3.35

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.66x
Working Capital Turnover Ttm:7.36x

Receivables Management (2)

Receivables Turnover Ttm:5.05x
Days Sales Outstanding Ttm:72.25

Inventory Management (2)

Inventory Turnover Ttm:3.41x
Days Inventory Outstanding Ttm:107.16

Payables & Cash Cycle (2)

Days Payable Outstanding:71.95
Cash Conversion Cycle:107.45
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:55.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (4)

Reinvestment Rate:-98.7%
Fundamental Growth Rate (g):-6.9%
Market-Implied Growth Rate:10.6%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:RYLPF
Company Name:KONINKLIJKE PHILIPS NV
Sector:Healthcare
Industry:X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Exchange:OTC
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:962.92M
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-23 23:27:50 UTC
Data Timestamp:2026-08-23T23:27:50.736611
Scroll to Top